• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A Case Of Hemophagocytic Lymphohistiocytosis Syndrome In A Patient With Multiple Sclerosis On Fingolimod Therapy. (P2.206)
CONCLUSIONS:As far as we know, this syndrome has never been reported in fingolimod treated patients. EBV reactivation may have been the triggering factor of HLH in our patient. Whether fingolimod contributed to HLH, through a direct mechanism, or indirectly favoring EBV reactivation, remains unknown. Our case highlights the diagnostic challenge of HLH and the need of monitoring and reporting serious adverse events in patients exposed to new IMD. Study Supported by:Disclosure: Dr. Abreu has received personal compensation for activities with Bayer Pharmaceuticals Corporation, Novartis, and Biogen Idec. Dr. Peixoto has nothin...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Abreu, P., Peixoto, C., Carvalho, C., Santos, L., Sarmento, A., Jose Sa, M. Tags: MS and CNS Inflammatory Disease: Treatment Safety Source Type: research

Reversible Cerebral Vasoconstriction Syndrome and Fingolimod: Culprit or Innocent Bystander (P2.224)
CONCLUSIONS:Reversible cerebral vasoconstriction syndrome may be a rare complication of Fingolimod treatment and should be considered in patients with new onset thunderclap headache. The mechanism likely involves the effects of Fingolimod on S1P(3) receptors on cerebral arteries.Disclosure: Dr. Fleming has nothing to disclose. Dr. West has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Fleming, J., West, M. Tags: MS and CNS Inflammatory Disease: Treatment Safety Source Type: research